Article Text

PDF
FRI0029 IL-7-driven T cell activation and toll-like receptor 7 triggering cause additive B cell activation that is further enhanced by monocytes
  1. A. Bikker,
  2. K.M. van der Wurff-Jacobs,
  3. A.A. Kruize,
  4. R.P. Peters,
  5. J.W. Bijlsma,
  6. F.P. Lafeber,
  7. J.A. van Roon
  1. Rheumatology & Clinical Immunology, Umc Utrecht, Utrecht, Netherlands

Abstract

Background IL-7 is a potent T cell activating cytokine that has been shown to cause proliferation, survival and differentiation of T cells as well as T cell-dependent activation of myeloid cells in numerous conditions. In inflamed tissues of patients with several autoimmune diseases (RA, pSS, psoriasis) increased IL-7 production by tissue cells and immune cells has been documented. Although reduced serum immunoglobulin levels in IL-7R-deficient individuals suggested that IL-7 might play a role in activation of mature human B cells, direct evidence for this is lacking. Previously, it has been demonstrated that EBV, one of the suggested triggers of pSS, induces TLR7-dependent B cell activation and that EBV-transformed B cells express significant levels of the IL-7R as well as IL-7. Furthermore, we have shown that both intracellular IL-7R and IL-7 expression is up regulated in vitro upon TLR7 triggering of B cells.

Objectives To investigate the potential synergy of IL-7-driven T cell-dependent and TLR7-mediated B cell activation and to assess the additive effects of monocyte/macrophages in this respect.

Methods Isolated CD19 B cells and CD4 T cells from HC (n=7) were co-cultured (1:1) with and without IL-7, TLR7 agonist (TLR7A, Gardiquimod) or the combination of IL-7/TLR7A with and without CD14 monocytes/macrophages (T/B/mono; 1:1:0,1). Proliferation of T and B cells was measured using 3H-thymidine incorporation and by Ki67 expression (FACS analysis). Activation markers (CD19, HLA-DR, CD25) expression were measured by FACS analysis.

Results Exogenously added IL-7 did not activate B cells directly, in line with the absence of surface IL-7R. However, in the presence of T cells, IL-7 activated both T and B cells (Ki67+ CD4 cells from 1.1±0.2% to 14.4±3.7%, p<0.01 and Ki67+ B cells from 1.9±0.3% to 4.1±0.9%, p<0.05). TLR7A induced B cell activation, as measured by increased proliferation (%Ki67 from 1.2±0.2% to 9.3±1.4%) and up regulation of activation markers on B cells, which was facilitated in the presence of monocytes. TLR7-induced B cell activation in T/B or T/B/monocyte co-cultures was not associated with T cell activation. IL-7 added to TLR7A synergistically increased both B cell (TLR7A vs. IL-7/TLR7A; 9.3±1.4% vs. 33.4±7.3%) and T cell proliferation (IL-7 vs. IL-7/TLR7A; 0.8±0.1% vs. 29.2±5.2%), which for B cells again was further increased by monocytes (TLR7A vs. IL-7/TLR7A; 30.2±8.9% vs. 63.0±8.0%). Similar results were observed for activation marker expression on B cells (CD19, HLA-DR CD25) and on T cells (HLA-DR, CD25).

Conclusions IL-7-induced T cell activation and TLR7A-induced B cell activation synergistically activate B cells, which is markedly enhanced by the presence of monocytes. Our results indicate that previously described increased local expression of IL-7 and TLR7 and increased numbers of macrophages could contribute to enhanced lymphocyte activation in patients with pSS.

Disclosure of Interest None Declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.